Shares of Endo International PLC (NASDAQ:ENDP) have been assigned a consensus rating of “Hold” from the twenty-four brokerages that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $16.73.

Several research firms have recently issued reports on ENDP. William Blair reaffirmed a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Stifel Nicolaus downgraded shares of Endo International PLC from a “buy” rating to a “hold” rating and dropped their price target for the company from $22.00 to $15.00 in a research note on Friday, June 9th. Vetr raised shares of Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price target for the company in a research note on Wednesday, May 17th. Canaccord Genuity set a $14.00 price target on shares of Endo International PLC and gave the company a “hold” rating in a research note on Monday, May 22nd. Finally, BMO Capital Markets reaffirmed a “hold” rating and set a $15.00 price target on shares of Endo International PLC in a research note on Monday, May 1st.

ILLEGAL ACTIVITY WARNING: “Endo International PLC (NASDAQ:ENDP) Given Consensus Recommendation of “Hold” by Brokerages” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/08/endo-international-plc-nasdaqendp-given-consensus-recommendation-of-hold-by-brokerages.html.

Endo International PLC (ENDP) traded down 12.14% during midday trading on Tuesday, reaching $8.18. 22,056,417 shares of the company’s stock were exchanged. The company’s market cap is $1.83 billion. The firm has a 50-day moving average price of $11.45 and a 200 day moving average price of $11.76. Endo International PLC has a 12-month low of $8.15 and a 12-month high of $24.93.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The firm had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The company’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.86 earnings per share. On average, analysts expect that Endo International PLC will post $3.53 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of ENDP. First Quadrant L P CA acquired a new position in shares of Endo International PLC during the first quarter worth about $24,556,000. OppenheimerFunds Inc. boosted its position in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock worth $32,065,000 after buying an additional 1,857,678 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock worth $25,345,000 after buying an additional 633,904 shares in the last quarter. Diamond Hill Capital Management Inc. acquired a new position in shares of Endo International PLC during the second quarter worth about $5,454,000. Finally, Ameriprise Financial Inc. boosted its position in shares of Endo International PLC by 685.0% in the first quarter. Ameriprise Financial Inc. now owns 554,138 shares of the company’s stock worth $6,185,000 after buying an additional 483,545 shares in the last quarter. Hedge funds and other institutional investors own 93.00% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Stock Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related stocks with our FREE daily email newsletter.